Prot# ALN-TTRSC02-002: HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis(hATTR Amyloidosis)

Project: Research project

StatusActive
Effective start/end date2/22/192/22/22

Funding

  • Medpace, Inc. (Prot# ALN-TTRSC02-002)
  • Alnylam Pharmaceuticals, Inc. (Prot# ALN-TTRSC02-002)